NAME



NAME Theresa J. Ochoa		POSITION TITLE Assistant Professor of Pediatrics and Epidemiology
eRA COMMONS USER NAME TOCHOA
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION	DEGREE		YEAR(s)	FIELD OF STUDY
Universidad Peruana Cayetano Heredia, Perú	BS		4/89 - 3/91	Biology
Universidad Peruana Cayetano Heredia, Perú	MD		4/89 - 3/97	Medicine
Universidad Peruana Cayetano Heredia, Perú			6/98 - 12/01	Pediatrics
University of Texas-Houston, Medical School, TX			1/02 - 12/04	Infectious Diseases
Baylor College of Medicine, Houston, TX			1/05 - 09/06	Research fellowship

1997 - 1998 Medical Rural Service of Perú. Centro de Salud Urubamba, Cusco, Perú (Peruvian Health Ministry).

1997 – 1998 Voluntary physician for a outpatient clinic in Urubamba, Cusco, in the Andes of Perú.

1998 - 2001 Medical Residency, Pediatrics, Univeridad Peruana Cayetano Heredia and Hospital Nacional Cayetano Heredia, Lima, Perú.

2002 - 2004 Clinical Fellow in Pediatric Infectious Diseases, University of Texas Health Science Center at Houston, Medical School, Houston, TX.

2005 - 2006 Fogarty Post Doctoral Fellow, Department of Medicine, Baylor College of Medicine, Houston, TX.

2005 – pres Assistant Professor, Department of Pediatrics, Universidad Peruana Cayetano Heredia, Lima, Perú.

2006 – pres Assistant Professor, Division of Epidemiology, School of Public Heath, University of Texas Health Science Center at Houston.

1991 First Place in the Area of Public Health in the 5th National Scientific Congress of Medical Students. Lambayeque, Perú (Educational proposal on tuberculosis).

1992 First Place in the Area of Basic Sciences and First Place Overall Award in the 6th National Scientific Congress of Medical Students. Cusco, Perú (Medical plants on gastric lesions).

1993 First Place in the Area of Basic Sciences in the 7th National Scientific Congress of Medical Students. Arequipa, Perú (Medical plants on gastric lesions).

1995 Winner of the I Biannual “Pedro Weiss Award” for research by medical students in Cayetano Heredia University. Lima, Perú (Medical plants on gastric lesions).

2000 Winner of the prize “FAIF 2000” (Fondo de Apoyo al Investigador Farmaindustria). Award for scientific projects by medical residents in Perú (S. pneumoniae carriers).

2002 Travel Grant Award to present research at the 11th International Conference of the International Society for Research in Human Milk and Lactation (ISRHML). Mexico, October 2002 (Entropathogenic E. coli and lactoferrin).

2003 Travel Grant “George McCracken Infectious Disease Fellow” to present research at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICCAC). Chicago, September 2003 (Enteropathogenic E. coli and lactoferrin).

2005 Young Investigator Award, VII International Conference on lactoferrin. Hawaii, October, 2005 (Enteroaggregative E. coli and lactoferrin)

2005 Winner of the XV Jornadas Científicas (Research Day) of Universidad Peruana Cayetano Heredia, for the Faculty of Medicine. Lima, September, 2005 (Enteroaggregative E. coli and lactoferrin)

2006 Internacional Young Investigator Travel Award. 44^th Annual Meeting of the Infectious Diseases Society of America (IDSA). Toronto, Canada, October 12-15, 2006 (Diarrheagenic E. coli in Peruvian children).

2007 Young Investigator Award 2007. Universidad Peruana Cayetano Heredia. Lima, September, 2007.

1. Gomez HF, Ochoa TJ, Herrera-Insua I, Carlin LG, Cleary TG. Lactoferrin protects rabbits from Shigella flexneri induced inflammatory enteritis. Infect Immun 2002;70(12):7050-3.

2. Gomez HF, Ochoa TJ, Carlin LG, Cleary TG. Human lactoferrin impairs virulence of Shigella flexneri. The J Infect Dis 2003;187:87-95.

3. Noguera-Obenza M, Ochoa TJ, Gomez HF, Guerrero ML, Herrera-Insua I, Morrow AL, Ruiz-Palacios G, Pickering LK, Guzman CA and Cleary TG. Human secretory antibodies against Attaching and Effacing Escherichia coli antigens. Emerg Infect Dis 2003;9(5):545-51.

4. Ochoa TJ, Noguera-Obenza M, Ebel F, Guzman CA, Gomez HF and Cleary TG. Lactoferrin impairs Type III Secretory System Function in Enteropathogenic E. coli. Infect Immun 2003;71(9):5149-55.

5. Ochoa TJ and Cleary TG. Epidemiology and spectrum of disease E. coli O157. Curr Opin Infect Dis 2003;16:259-63.

6. Ochoa TJ, Salazar-Lindo E and Cleary TG. Evaluation of children with persistent infectious diarrhea. Sem Pediatr Infect Dis. 2004;15(4):229-236.

7. Ochoa TJ and Cleary TG. Lactoferrin disruption of bacterial Type III Secretion Systems. BioMetals. 2004;17(3): 257-260.

8. Ochoa TJ, Noguera-Obenza M and Cleary TG. Lactoferrin blocks the initial host cell attachment mechanism of Enteropathogenic E. coli (EPEC). Adv Experl Med Biol. 2004;554:463-466

9. Ochoa TJ and White AC Jr. Nitazoxanide for treatment of intestinal parasites in children. Pediatric Infectious Diseases Journal. 2005;24(7):641-642.

10. Ochoa TJ, Rocio R, Guerra H, Hernandez H, Chaparro E, Tamariz J, Wanger A and Mason EO. Penicillin resistance and serotypes/serogroups of Streptococcus pneumoniae in nasopharyngeal carrier children younger than 2 years in Lima, Perú. Diagnostic Microbiology and Infectious Diseases. 2005;52(1):59-64.

11. Ochoa TJ, Mohr JF, Wanger A, Murphy JR and Heresi GP. Community-associated Methicillin-resistant Staphylococcus aureus in pediatric patients. Emerging Infectious Diseases. 2005;11(6):966-968.

12. Estrada-García T, Cerna JF, Pacheco-Gil L, Velázquez RF, Ochoa TJ, Torres J and DuPont HL. Drug-resistant Diarrheogenic Escherichia coli, Mexico. Emerging Infectious Diseases. 2005;11(8):1306-1308.

13. Ochoa TJ, Rojas R, Gutierrez M and Porturas D. Severe airway obstruction in a child with Pott’s disease. Pediatric Infectious Diseases Journal, 2006; 25(7):649-51.

14. Pacheco-Gil L, Ochoa TJ, DuPont HL and Estrada-García T. Enteroinvasive Escherichia coli severe dysentery complicated by rotavirus gastroenteritis. J Infect. 2006, Nov 53 (5):e211-3.

15. Ochoa TJ, Brown EL, Guion CE, Chen JZ, McMahon RJ and Cleary TG. Effect of lactoferrin on Enteroaggregative E. coli (EAEC). Biochemistry and Cell Biology, 2006;84(3):369-376.

16. Ochoa TJ, Chen JZ, Walker CM, and Cleary TG. Rifaximin does not induce Shiga toxin (Stx) production or phage-mediated lysis of Shiga toxin producing E. coli (STEC). Antimicrobial Agents and Chemotherapy. 2007 Aug;51(8):2837-41.

18. Ochoa TJ and Cleary TG. Effect of lactoferrin on enteric pathogens. Biochimie. 2008 Apr 18. [Epub ahead of print]

19. Ochoa TJ, Chea-Woo E, Campos M, Pecho I, Prada A, McMahon, RJ, Cleary TG. Impact of Lactoferrin Supplementation on Growth and Prevalence of Giardia Colonization in Children.Clin Infect Dis. 2008 May 5. [Epub ahead of print]

20. Ochoa TJ, Barletta F, Contreas C, Mercado E. New insights into the epidemiology of enteropathogenic Escherichia coli infection. Trans R Soc Trop Med Hyg. 2008 May 1. [Epub ahead of print]